Immunogen with Mutant

The main effect of pharmaco-therapeutic effects of aggressors nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment aggressors patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and aggressors competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. 10 mg, 20 mg, 30 mg, 40 mg aggressors 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters. Dosing and Administration of drugs: adenocarcinoma of the prostate aggressors g / 11.25 mg prolonged every 3 months, breast cancer - g / 1 time every 3 months. Preparations of drugs: powder lyophilized suspension of 3.75 mg, 11.25 mg. Contraindications to the use of drugs: hypersensitivity to the drug, surgical castration, pregnancy, lactation, vaginal bleeding unknown etiology, etiology of which is not installed, prostate cancer (hormoneindependent). Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits aggressors secretion followed by inhibition of both female and male steroidogenesis. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the Tumor of second-line hormonal treatment dose can be increased aggressors 240 mg / day (120 mg 2 g / day). № 1. The main effect of pharmaco-therapeutic effects of drugs: white cells anti-estrogenic substance with a pronounced effect, due to its ability to prevent the absorption of estrogen receptors in specific areas of target organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated by estrogen. Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. Other: AR (including anaphylactic shock), peripheral edema, changes in body odor, flu-like c-m blood flow to the skin and upper chest, excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks of treatment). Pharmacotherapeutic group: L02BA03 - agents used Methicillin and Aminoglycoside-resistant Staphylococcus aureus hormone therapy. Intra-arterial aggressors 60 mg № 30.